盘龙药业(002864.SZ)：氟比洛芬贴剂获准开展临床试验

Core Viewpoint - The company, Panlong Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its drug, Flurbiprofen patch, targeting pain relief and anti-inflammatory effects for various conditions [1] Group 1: Clinical Trial Approval - The National Medical Products Administration has issued a Clinical Trial Approval Notice for the Flurbiprofen patch [1] - The approved indications for the clinical trial include osteoarthritis, periarthritis of the shoulder, tendinitis, tenosynovitis, peritendinitis, lateral epicondylitis (such as tennis elbow), muscle pain, and swelling and pain after injury [1]